PathWhiz

Pathway Description

Prasugrel Action

Homo sapiens

Drug Action Pathway

References

Prasugrel Action References

Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S: The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost. 2008 Jul;6(7):1153-9. doi: 10.1111/j.1538-7836.2008.03020.x. Epub 2008 Jul 1.

Pubmed: 18485086

Angiolillo DJ: The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116. doi: 10.2165/11640880-000000000-00000.

Pubmed: 23083110

Dean L: Prasugrel Therapy and CYP Genotype

Pubmed: 28520385

Tagarakis GI: Ticagrelor and prasugrel: two novel, most-promising antiplatelet agents. Recent Pat Cardiovasc Drug Discov. 2010 Nov;5(3):208-11.

Pubmed: 20874669

Highlighted elements will appear in red.

Highlight Compounds

	Adenosine diphosphate
	Calcium
	cAMP
	Magnesium

Highlight Proteins

	Adenylate cyclase type 10
	Guanine nucleotide-binding protein G(i) subunit alpha-1
	P2Y purinoceptor 12
	Unknown

Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.

Visualize Compound Data